A clinical trial is underway in Israel to investigate whether the Bacillus Calmette-Guérin (BCG) vaccine, traditionally used to prevent tuberculosis, can also slow the progression of Alzheimer's disease. Neurologist Tamir Ben-Hur at Hadassah-University Medical Center in Jerusalem is leading the study, which explores the vaccine's potential to modulate the immune system and protect the brain.
The study is based on previous findings suggesting that the BCG vaccine may reduce the risk of developing Alzheimer's disease by strengthening the immune system. The theory posits that the BCG vaccine activates systemic and brain immune cells, potentially shielding the brain from the pathological changes associated with Alzheimer's.
Trial Design and Objectives
The clinical trial is designed to directly assess the effectiveness of the BCG vaccine in preventing Alzheimer's. Participants undergo initial cognitive assessments and blood tests to determine their eligibility. These tests measure biomarkers, including the level of phosphorylated tau protein, which is indicative of Alzheimer's risk. Individuals who show biomarkers associated with a higher likelihood of developing Alzheimer's may receive three doses of the BCG vaccine.
Follow-up evaluations include additional blood tests and cognitive assessments to monitor changes in biomarker levels and cognitive function. The primary endpoint is to determine if the BCG vaccination reduces the level of phosphorylated tau protein and other relevant biomarkers in the blood, indicating a reduced risk of developing dementia over several years.
Broader Research Implications
In addition to evaluating the BCG vaccine, the trial incorporates basic research aimed at identifying systemic factors that drive Alzheimer's disease. By analyzing blood samples from participants, researchers hope to uncover novel insights into the underlying mechanisms of the disease and identify potential targets for future drug development.
BCG Vaccine and Tuberculosis Prevention
The BCG vaccine has been used since 1921 to prevent tuberculosis. In Israel, newborns were routinely vaccinated as part of a public health initiative. Currently, only babies at high risk receive the vaccine, as its effectiveness against tuberculosis is limited. The trial leverages the vaccine's known immunomodulatory effects to explore its potential in preventing Alzheimer's disease.
Call for Participation
The study is actively recruiting participants. Individuals interested in joining the trial can contact the research team at 055-220-4061 or fightAD23@gmail.com.
